Myriad Genetics (MYGN) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Myriad Genetics (MYGN) Tops Q2 EPS by 4c

Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress

February 3, 2016 8:07 AM EST

Mizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings report. MYGN beat consensus revenues by $5mm and EPS by $0.04. However, Mizuho remains sidelined until more progress on reimbursement is seen.

Analyst Eric Criscuolo... More